FY2028 Earnings Forecast for TNXP Issued By Zacks Research

Key Points

• Zacks Research issued a FY2028 earnings forecast of $1.97 EPS for Tonix Pharmaceuticals, a dramatic divergence from the article’s cited current consensus estimate of ($1,762.50) per share.
• In the latest quarter Tonix reported a loss of ($3.98) EPS, missing estimates by $0.82 while reporting revenue of $5.39 million, and showing a negative return on equity (60.15%) and a net margin of -946.22%.
• Corporate insiders remain minimally vested but CEO Seth Lederman bought 15,000 shares at $14.89 recently, and institutional investors own about 82.26% of the company amid mixed analyst ratings and a MarketBeat consensus of "Hold."

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities research analysts at Zacks Research issued their FY2028 earnings estimates for Tonix Pharmaceuticals in a note issued to investors on Monday, March 23rd. Zacks Research analyst D. Bautz anticipates that the company will post earnings per share of $1.97 for the year. The consensus estimate for Tonix Pharmaceuticals' current full-year earnings is ($1,762.50) per share.

Several other analysts have also weighed in on TNXP. Weiss Ratings restated a "sell (e+)" rating on shares of Tonix Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, January 17th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Tonix Pharmaceuticals presently has a consensus rating of "Hold".

Tonix Pharmaceuticals Stock Performance

Shares of Tonix Pharmaceuticals stock opened at $15.34 on Wednesday. The stock has a market cap of $205.56 million, a price-to-earnings ratio of -1.07 and a beta of 1.88. The stock has a 50 day moving average price of $15.58 and a 200-day moving average price of $18.17. Tonix Pharmaceuticals has a one year low of $13.07 and a one year high of $69.97.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($3.98) earnings per share for the quarter, missing the consensus estimate of ($3.16) by ($0.82). The company had revenue of $5.39 million for the quarter, compared to the consensus estimate of $2.97 million. Tonix Pharmaceuticals had a negative return on equity of 60.15% and a negative net margin of 946.22%.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A number of large investors have recently bought and sold shares of TNXP. Legal & General Group Plc bought a new position in Tonix Pharmaceuticals in the 2nd quarter valued at $25,000. State of Wyoming bought a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth $27,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Tonix Pharmaceuticals during the second quarter valued at $28,000. Russell Investments Group Ltd. purchased a new stake in shares of Tonix Pharmaceuticals during the third quarter valued at $29,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in shares of Tonix Pharmaceuticals in the second quarter worth about $62,000. Hedge funds and other institutional investors own 82.26% of the company's stock.

Insider Activity at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman bought 15,000 shares of the business's stock in a transaction dated Wednesday, March 18th. The shares were purchased at an average price of $14.89 per share, with a total value of $223,350.00. Following the completion of the purchase, the chief executive officer owned 15,001 shares in the company, valued at $223,364.89. This represents a 1,500,000.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.03% of the company's stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company's pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix's lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.